---
schema_version: "secwatch.filing_event.v1"
accession: "0001544227-22-000004"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:34:10.204348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tempest Q3 2022 net loss $8.9M; cash at $42.8M; pipeline milestones on track

## Summary
- Cash and equivalents $42.8M as of Sep 30, 2022, down from $51.8M at Dec 31, 2021.
- Net loss Q3 2022 of $8.9M ($0.66/sh) vs $8.1M ($1.21/sh) in Q3 2021.
- R&D expense increased to $6.0M from $4.6M on expanded R&D efforts.
- TPST-1120 Phase 1b/2 HCC study with Roche; early data from first 40 patients expected H1 2023.
- TPST-1495 Phase 1 dose optimization data expected by year-end or early 2023.

## SEC filing metadata
- accession: 0001544227-22-000004
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/tpst-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001544227-22-000004
- JSON: https://secwatch.observer/filing/0001544227-22-000004.json
- Plain text: https://secwatch.observer/filing/0001544227-22-000004.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the third fiscal quarter ended September 30, 2022 results: net income $8.9 million, EPS $0.66.
  - Period: the third fiscal quarter ended September 30, 2022
  - Net income: $8.9 million
  - EPS: $0.66
  - Result: reported results
  source text: Net loss and net loss per share for the third quarter of 2022 were $8.9 million and $0.66, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.